Skip to main content

Table 3 Class of biologics taken in the BMD <70 % of YAM and BMD ≥70 % of YAM groups

From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics

  BMD <70 % of YAM BMD ≥70 % of YAM
TNFα inhibitor 26 66
Tocilizumab 6 16
Abatacept 3 9
Switch biologics 22 38
  1. (p = 0.67)
  2. BMD bone mineral density, YAM young adult mean, TNFα tumor necrosis factor-α